Trials / Completed
CompletedNCT04349163
Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period : Prospective Cohort.
Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 280 (actual)
- Sponsor
- University Hospital, Angers · Other Government
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
The outbreak linked to SARS-CoV-2 infection was declared a Public Health Emergency of International Concern on 30 January 2020. In all of the emergency Departments, a major reorganization was necessary, notably with the creation of a specific channel for COVID-19 suspect patients. Thus, all caregivers involved must adapt day by day to new places of exercise, new protocols,...The major influx of patients, the precautions to be taken, the specifics of the pathology and its management have profoundly changed daily practice. This exogenous hospital tension impacts all caregivers and more particularly their resilience capacities. Resilience is defined as an ability to recover from or adjust easily to misfortune or change. The Resi-CoV study aims to assess the level of resilience of caregivers of different specialties and trades in the context of covid-19.
Detailed description
Caregivers will be invited to complete a self-administered questionnaire online via a personalized electronic message. Caregivers will be free to participate. Signed consent will not be requested, but the return of the questionnaire will be considered consent. The questionnaire will be administered using Google form® software. Caregivers will have 2 weeks to respond. A reminder will be made at 7 days. The questionnaire will be anonymized upon receipt by the investigator.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Questionnaire | CD-RISC 25 questionnaire |
Timeline
- Start date
- 2020-05-10
- Primary completion
- 2020-06-15
- Completion
- 2020-06-25
- First posted
- 2020-04-16
- Last updated
- 2020-09-23
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04349163. Inclusion in this directory is not an endorsement.